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N-acetyltransferase 2 polymorphisms are of high relevance in clinical toxicology (Lück et al., 2009\[[@R29]\]; Bing et al., 2011\[[@R4]\]; Costa et al., 2012\[[@R9]\]). The slow acetylator genotype of NAT2 has been demonstrated to be associated with an increased risk of anti-tuberculosis drug-induced liver damage (Cai et al., 2012\[[@R7]\]; Lv et al., 2012\[[@R30]\]; An et al., 2012\[[@R2]\]; Ben Mahmoud et al., 2012\[[@R3]\]; Bose et al., 2011\[[@R6]\]). Moreover, many urinary bladder carcinogens are substrates of NAT2 (Golka et al., 1996\[[@R16]\]; 2002\[[@R15]\]; Vineis et al., 2001\[[@R44]\]; Hung et al., 2004\[[@R25]\]; Moore et al., 2011\[[@R31]\]). Large meta-analyses have clearly shown an association between slow acetylation genotypes and increased risk of bladder cancer (Garcia-Closas et al., 2005\[[@R14]\]; 2011\[[@R13]\]; Sanderson et al., 2007\[[@R34]\]; Agúndez et al., 2008\[[@R1]\]; Hein, 2002\[[@R20]\], 2006\[[@R21]\], 2009\[[@R22]\]; Hein and Doll, 2012\[[@R23]\]\[[@R24]\]). However, at the level of individual studies the results remain controversial. Of 46 studies included into one of the recent meta-analysis 35 did not reach statistical significance (Moore et al., 2011\[[@R31]\]).

To clarify the situation a recent study has been performed to identify the role of \'extreme\' genotypes (Selinski et al., 2013\[[@R36]\]). This study is based on a population of 344 individuals that have been phenotyped by the caffeine test (Blaszkewicz, 2004\[[@R5]\]; Hakooz, 2009\[[@R18]\]; Jetter et al., 2009\[[@R26]\]). This test quantitatively determines the activity of NAT2 *in vivo*. A subgroup with an \`ultra-slow´ *in vivo* metabolism of caffeine was identified.

Interestingly, these individuals with the ultra-slow NAT2 phenotype carried several slow acetylator alleles and could be identified as \*6A/\*6A, \*6A/\*7B and \*7B/\*7B genotypes. This combination of slow alleles, the \'ultra-slow genotype\' was further tested in 1,712 bladder cancer cases and 2,020 controls. Remarkably, individuals with the \'ultra-slow\' genotype showed an increased odds ratio for bladder cancer risk (OR=1.31, P=0.012) whereas the slow acetylators in general were not significantly associated with cancer risk.

Currently, a huge number of studies is performed to understand the association between genetic variations and phenotype (Daly, 2013\[[@R10]\]; Stewart and Marchan, 2012\[[@R41]\]; Partosch et al., 2013\[[@R32]\]; Sobin et al., 2011\[[@R40]\]; Tumer et al., 2012\[[@R42]\]; Zeller et al., 2012\[[@R45]\]; Escobar-García et al., 2012\[[@R11]\]). A special focus are drug metabolizing enzymes and their role in carcinogenesis (Chen et al., 2012\[[@R8]\]; Hanioka et al., 2011\[[@R19]\]; Santovito et al., 2011\[[@R35]\]; Fujihara et al., 2011\[[@R12]\]; Lankisch et al., 2008\[[@R27]\]; Ulusoy et al., 2007\[[@R43]\]). Genome-wide association studies have identified to which degree genetic variants influence bladder cancer risk (Golka et al., 2011\[[@R17]\]; Selinski et al., 2011\[[@R37]\], 2012\[[@R38]\]\[[@R39]\]; Safarinejad et al., 2011\[[@R33]\]; Lehmann et al., 2010\[[@R28]\]). However, most of these approaches considered only the genotype in relation to disease. The present study (Selinski et al., 2013\[[@R36]\]) demonstrates the importance of understanding the association of haplotypes with enzyme activity and the relevance of extreme phenotypes.
